Subjective effects of antipsychotic drugs and their relevance for compliance and remission

Epidemiologia e Psichiatria Sociale

Volumn 17, Issue 3, 2008, Pages 174-176

  Naber, Dieter ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; OLANZAPINE;

ANHEDONIA; BLUNTED AFFECT; CLINICAL DECISION MAKING; CLINICAL TRIAL; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEPRESSION; DISEASE SEVERITY; DOPAMINE RECEPTOR BLOCKING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; EDITORIAL; HUMAN; INDIVIDUALIZATION; LONG TERM CARE; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROBIOLOGY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PATIENT ATTITUDE; PATIENT AUTONOMY; PATIENT COMPLIANCE; PATIENT PARTICIPATION; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; PROGNOSIS; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; PSYCHOSOCIAL CARE; QUALITY OF LIFE; RELIABILITY; REMISSION; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SELF CONCEPT; SELF REPORT; SIDE EFFECT; SOCIAL PSYCHOLOGY; TEMPORAL LOBE; UNSPECIFIED SIDE EFFECT; WELLBEING;

EID: 53849119149     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1121189X00001238     Document Type: Editorial

References (23)

1. Balestrieri M., Giaroli G., Mazzi M. & Bellantuono C. (2006). Performance of the Italian Version of the Subjective Well-being under Neuroleptic (SWN) Scale in Schizophrenic Outpatients. Pharmacopsychiatry 39, 81-84.
2. De Haan L., Lavalaye J., Linszen D., Dingemans P.M. & Booje J. (2000). Subjective experiences and striatal dopamine D2 receptor occupancy in patients with recent onset schizophrenia treated with olanzapine or risperidone. American Journal of Psychiatry 157, 1019-1020.
3. De Haan L., Weisfelt M., Dingemans P.M., Linszen D.H. & Wouters L. (2002). Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology 162, 24-28.
4. Heinrichs D.W., Hanlon T.E. & Carpenter W.T. (1984). The Quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophrenia Bulletin 10, 388-398.
5. Hogan T.P., Awad A.G. & Eastwood M.R. (1983). A self-report scale predictive of drug compliance in schizophrenia: reliability and discriminate validity. Psychological Medicine 13, 177-183.
6. Karow A. & Naber D. (2002). Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology 162, 3-10.
7. Karow A., Czekalla J., Dittmann R.W., Schacht A., Wagner T., Lambert M., Schimmelmann B.G. & Naber D. (2007). Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. Journal of Clinical Psychiatry 68, 75-80.
8. Lambert M., Schimmelmann B.G., Naber D., Schacht A., Karow A., Wagner T. & Czekalla J. (2006). Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. Journal of Clinical Psychiatry 67, 1690-1697.
9. Lambert M., Naber D., Eich F.X., Schacht A., Linden M. 6 Schimmelmann B.G. (2007). Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scandinavica 115, 106-113.
10. Meltzer H.Y., Burnett S., Bastani B. & Ramirez L.F. (1990). Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hospital Community Psychiatry 41, 892-897.
11. Mizrahi R., Rusjan P., Agid O., Graff A., Mamo D.C., Zipursky R.B. & Kapur S. (2007). Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia. American Journal of Psychiatry 164, 630-637.
12. Naber D. (1995). A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life and other clinical variables. International Clinical Psychopharmacology 10, Suppl. 3, 133-138.
13. Naber D. (2005). Subjective effects of antipsychotic treatment. Acta Psychiatrica Scandinavica 111, 81-83.
14. Naber D., Moritz S., Lambert M., Pajonk F.G., Holzbach R., Mass R. & Andresen B. (2001). Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs. Schizophrenia Research 50, 79-88.
15. Naber D., Riedel M., Klimke A., Vorbach E.U., Lambert M., Kühn K.U., Bender S., Bandelow B., Lemmer W., Moritz S. & Dittmann R.W. (2005). Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatrica Scandinavica 111, 106-115.
16. Putzhammer A., Perfahl M., Pfeiff L. & Hajak G. (2005). Correlation of subjective well-being in schizophrenic patients with galt parameters, expert-rated motor disturbances, and psychopathological status. Pharmacopsychiatry 38, 132-138.
17. van Putten T., May P.R.A. & Marder S.R. (1981). Subjective response to antipsychotic drugs. Archives of General Psychiatry 38, 187-190.
18. Voruganti L. & Awad A.G. (2004). Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology 171, 121-132.
19. Voruganti K., Heslegrave R.J., Awad A.G. & Seeman M.V. (1998). Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychological Medicine 28, 165-172.
20. Voruganti L., Cortese L., Oyewumi L., Cernovsky Z., Zirul S. & Awad A. (2000). Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophrenia Research 43, 135-145.
21. Wehmeier P.M., Kluge M., Schneider E., Schacht A., Wagner T. & Schreiber W. (2007a). Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Progress in Neuropsychopharmacology & Biological Psychiatry 31, 703-712.
22. Wehmeier P.M., Kluge M., Schacht A., Helsberg K. & Schreiber W. (2007b). Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophrenia Research 91, 178-186.
23. Windgassen K. (1992). Treatment with neuroleptics: the patient's perspective. Acta Psychiatrica Scandinavica 86, 405-410.